These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 30082856)
1. Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas. Arita H; Kinoshita M; Kawaguchi A; Takahashi M; Narita Y; Terakawa Y; Tsuyuguchi N; Okita Y; Nonaka M; Moriuchi S; Takagaki M; Fujimoto Y; Fukai J; Izumoto S; Ishibashi K; Nakajima Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Mori K; Ichimura K; Kanemura Y Sci Rep; 2018 Aug; 8(1):11773. PubMed ID: 30082856 [TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843 [TBL] [Abstract][Full Text] [Related]
3. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
4. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma. Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414 [TBL] [Abstract][Full Text] [Related]
5. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
6. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas. Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087 [TBL] [Abstract][Full Text] [Related]
7. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T; Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363 [TBL] [Abstract][Full Text] [Related]
8. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners. Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710 [TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma. Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841 [TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma. Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317 [TBL] [Abstract][Full Text] [Related]
13. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models. Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427 [TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas]. Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117 [No Abstract] [Full Text] [Related]
15. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322 [TBL] [Abstract][Full Text] [Related]
16. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas. Jiang C; Kong Z; Zhang Y; Liu S; Liu Z; Chen W; Liu P; Liu D; Wang Y; Lyu Y; Zhao D; Wang Y; You H; Feng F; Ma W Neuroradiology; 2020 Jul; 62(7):803-813. PubMed ID: 32239241 [TBL] [Abstract][Full Text] [Related]
17. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
18. Prediction of Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763 [TBL] [Abstract][Full Text] [Related]
19. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590 [TBL] [Abstract][Full Text] [Related]
20. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Killela PJ; Pirozzi CJ; Healy P; Reitman ZJ; Lipp E; Rasheed BA; Yang R; Diplas BH; Wang Z; Greer PK; Zhu H; Wang CY; Carpenter AB; Friedman H; Friedman AH; Keir ST; He J; He Y; McLendon RE; Herndon JE; Yan H; Bigner DD Oncotarget; 2014 Mar; 5(6):1515-25. PubMed ID: 24722048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]